<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075203</url>
  </required_header>
  <id_info>
    <org_study_id>C-040-404</org_study_id>
    <nct_id>NCT02075203</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents</brief_title>
  <official_title>A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aeras</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety,
      Immunogenicity, and Prevention of Infection with Mycobacterium tuberculosis of AERAS-404 and
      BCG Revaccination in Healthy Adolescents
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II, randomized, 3-arm, placebo controlled, partially blinded, clinical trial will
      be conducted in 990 healthy, HIV-uninfected, QFT-GIT negative, previously BCG vaccinated
      adolescents. The trial will be conducted at the South African Tuberculosis Vaccine Initiative
      (SATVI) site in the Western Cape region of South Africa, where epidemiological studies
      involving thousands of adolescents have been conducted over the last decade to characterize
      rates of Mtb infection and active TB disease in this age group. Subjects will be enrolled in
      two sequential cohorts and within each cohort subjects will be randomized in a 1:1:1 ratio to
      receive either AERAS-404 or saline placebo on Days 0 and 56, or BCG Vaccine SSI on Day 0. The
      first 90 subjects (30 from each arm) will form the Safety &amp; Immunogenicity Cohort and will be
      subject to more intensive collection of safety data, with data reviewed by the Data
      Monitoring Committee (DMC), principal investigator and local medical monitor. Selected
      immunogenicity assays, including whole blood intracellular cytokine staining (ICS), will also
      be performed in this cohort. The remaining 900 subjects will be enrolled into the Correlates
      Cohort. All 990 subjects in the study will be evaluated for safety and biomarker outcomes,
      and for prevention of Mtb infection.

      The primary Mtb infection endpoint will be QFT-GIT conversion from a negative to positive
      test, using the manufacturer's recommended threshold of 0.35 IU/mL, at any time-point after
      Day 84 and through end of follow-up for the primary endpoint. The 84-day 'wash-out' period is
      stipulated in order to exclude subjects who may have already been Mtb infected, but not yet
      converted their QFT-GIT test at screening, thus subjects who convert their QFT-GIT at Day 84
      will not be included in the analyses of prevention of Mtb infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">October 6, 2017</completion_date>
  <primary_completion_date type="Actual">August 28, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Profile of H4:IC31 and BCG Revaccination in HIV-uninfected, Remotely BCG Vaccinated Adolescents.</measure>
    <time_frame>Study day 7 thru 6 months after last vaccination</time_frame>
    <description>Number of unsolicited and solicited adverse events recorded post vaccination.
Unsolicited adverse events: 28 days post each vaccination
Solicited adverse events: 7 days post each vaccination (with diary cards used for 7 days after each vaccination for Safety and Immunogenicity Cohort only)
Solicited and unsolicited injection site reaction adverse events: BCG Group - 84 days post vaccination; H4:IC31/Placebo Groups - 28 days post each vaccination
Serious adverse events, adverse events of special interest, and SUSARs: Entire study period, with a minimum of 6 months following the last dose of study vaccine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Testing Positive for Mtb at Day 84</measure>
    <time_frame>Study day 84 through 6 months post-conversion</time_frame>
    <description>Rates of conversion to Mtb-positive measured by QuantiFERON-TB Gold In-tube (QFT-GIT) assay. The primary evaluation of Mtb infection was QFT-GIT conversion from a negative to positive test, using the manufacturer's recommended threshold of ≥0.35 IU/mL, at any time point after Day 84 and through end of follow-up for the primary endpoint. All participants with primary QFT-GIT conversion were followed for an additional 6 months post-conversion to ascertain the sustained QFT-GIT conversion and QFT-GIT reversion endpoints. Participants with an initial QFT-GIT conversion at Month 6 or 12 were asked to return for a final QFT-GIT evaluation and assessment for TB signs and symptoms at least 24 months after their initial vaccination.
H4:IC31 compared to placebo
BCG revaccination compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of Sustained Conversion to Mtb-positive</measure>
    <time_frame>6 months after initial conversion</time_frame>
    <description>Rates of sustained conversion to Mtb-positive as measured by QFT-GIT assay.
H4:IC31 compared to placebo
BCG revaccination compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Immune Response to Vaccine in HIV-uninfected, Remotely BCG-vaccinated Adolescents: o H4:IC31 o BCG Revaccination</measure>
    <time_frame>Study day 70</time_frame>
    <description>A 13 color intracellular cytokine staining assay (ICS) was performed on peripheral blood mononuclear cells (PBMC) to assess CD4+ T cells that expressed IFN-γ, TNF, IL-2, IL-17, IL-22, CD107a, and/or CD154 alone or in combination in response to stimulation with peptide pools representing the entire amino acid sequence of the TB mycobacterial antigens Ag85B and TB10.4, and BCG antigens. Responders were IFN-gamma and/or IL-2 positive.
An intracellular cytokine assay was performed on whole blood (WB) to measure the frequencies and patterns of CD4+ T cells expressing Th1 and Th17 cytokines following stimulation of whole blood with peptide pools representing the entire amino acid sequence of the TB mycobacterial antigens Ag85B and TB10.4, as well as viable BCG from the vaccine vial. Responders were IFN-gamma, IL-2, TNF, IL-17, and/or IL-22 positive.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">989</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>AERAS-404 (15 mcgH4/500 nmol IC31)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses on Study Days 0 and 56</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bacillus Calmette-Guérin (BCG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 Dose on Study Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 Doses on Study Days 0 and 56</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AERAS-404</intervention_name>
    <description>The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK &amp; a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 &amp; saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.</description>
    <arm_group_label>AERAS-404 (15 mcgH4/500 nmol IC31)</arm_group_label>
    <other_name>H4</other_name>
    <other_name>H4:IC31</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bacillus Calmette-Guérin (BCG)</intervention_name>
    <description>BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).</description>
    <arm_group_label>Bacillus Calmette-Guérin (BCG)</arm_group_label>
    <other_name>BCG</other_name>
    <other_name>BCG SSI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has completed the written informed consent and assent process

          2. Is age ≥ 12 years and ≤ 17 years on Study Day 0

          3. Agrees to stay in contact with the study site for the duration of the study, provide
             updated contact information

          4. For female subjects: agrees to avoid pregnancy from 28 days prior to Study Day 0 and
             for the full duration of the study.

          5. Has general good health, confirmed by medical history and physical examination

          6. Had BCG vaccination at least 5 years ago documented through medical history or by
             presence of healed BCG scar

          7. Tests QFT-GIT negative at screening, using the manufacturer's recommended threshold of
             0.35 IU/mL

        Exclusion Criteria:

          1. Acute illness on Study Day 0

          2. Oral temperature ≥37.5°C on Study Day 0

          3. Clinically significant (and no more than Grade 1 on the Toxicity Scale) abnormal
             laboratory values from blood collected within 21 days

          4. Evidence of clinically significant (and no more than Grade 1 on the Toxicity Scale)
             systemic or local disease on urinalysis

          5. History or evidence of any clinically significant systemic disease, or any acute or
             chronic illness that might affect the safety, immunogenicity, or efficacy of study
             vaccine in the opinion of the investigator

          6. History of treatment for active TB disease or latent Mtb infection

          7. History or evidence, including chest X-ray, of active TB disease

          8. Shared residence with an individual receiving anti-TB treatment, or known incompletely
             treated culture or smear positive TB

          9. History of autoimmune disease or immunosuppression

         10. Used immunosuppressive medication within 42 days before Study Day 0

         11. Received immunoglobulin or blood products within 42 days before Study Day 0

         12. Received any investigational drug therapy or investigational vaccine within 182 days
             before Study Day 0

         13. Received investigational TB vaccine, other than BCG

         14. Planned administration/administration of a licensed vaccine in the period starting 28
             days before and ending 28 days after each dose of study vaccine

         15. History or laboratory evidence of any past or present possible immunodeficiency state
             not limited to any lab indication of HIV-1 infection

         16. History of allergic disease likely to be exacerbated by any component of the study
             vaccine

         17. History of alcohol or drug abuse

         18. All female subjects: currently pregnant or lactating/nursing; or positive urine
             pregnancy test during screening

         19. Received a (TST) within 3 months (90 days) prior to Study Day 0.

         20. Any current medical, psychiatric, occupational, substance abuse problems problems that
             in opinion of investigator will make unlikely for the subject to comply with the
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Hatherill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The South African Tuberculosis Vaccine Initiative(SATVI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South African Tuberculosis Vaccine Initiative , Project Office, Brewelskloof Hospital , Harlem Street, Worcester</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation (DTHF)</name>
      <address>
        <city>Nyanga</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <results_reference>
    <citation>Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M; C-040-404 Study Team. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021.</citation>
    <PMID>29996082</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 17, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <results_first_submitted>February 14, 2019</results_first_submitted>
  <results_first_submitted_qc>May 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2019</results_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCG Vaccinated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02075203/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02075203/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 10, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02075203/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AERAS-404 (15 mcgH4/500 Nmol IC31)</title>
          <description>2 doses on Study Days 0 and 56
AERAS-404: The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK &amp; a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 &amp; saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.</description>
        </group>
        <group group_id="P2">
          <title>Bacillus Calmette-Guérin (BCG)</title>
          <description>1 Dose on Study Day 0
Bacillus Calmette-Guérin (BCG): BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>2 Doses on Study Days 0 and 56
Placebo: Saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="330"/>
                <participants group_id="P2" count="330"/>
                <participants group_id="P3" count="329"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="327"/>
                <participants group_id="P2" count="330"/>
                <participants group_id="P3" count="328"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>participant refused to use contraception</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AERAS-404 (15 mcgH4/500 Nmol IC31)</title>
          <description>2 doses on Study Days 0 and 56
AERAS-404: The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK &amp; a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 &amp; saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.</description>
        </group>
        <group group_id="B2">
          <title>Bacillus Calmette-Guérin (BCG)</title>
          <description>1 Dose on Study Day 0
Bacillus Calmette-Guérin (BCG): BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>2 Doses on Study Days 0 and 56
Placebo: Saline</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="330"/>
            <count group_id="B2" value="330"/>
            <count group_id="B3" value="329"/>
            <count group_id="B4" value="989"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="330"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="329"/>
                    <measurement group_id="B4" value="989"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="1.47"/>
                    <measurement group_id="B2" value="14.2" spread="1.49"/>
                    <measurement group_id="B3" value="14.3" spread="1.54"/>
                    <measurement group_id="B4" value="14.2" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="520"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="330"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="329"/>
                    <measurement group_id="B4" value="989"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="366"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="207"/>
                    <measurement group_id="B4" value="615"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="330"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="329"/>
                    <measurement group_id="B4" value="989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Profile of H4:IC31 and BCG Revaccination in HIV-uninfected, Remotely BCG Vaccinated Adolescents.</title>
        <description>Number of unsolicited and solicited adverse events recorded post vaccination.
Unsolicited adverse events: 28 days post each vaccination
Solicited adverse events: 7 days post each vaccination (with diary cards used for 7 days after each vaccination for Safety and Immunogenicity Cohort only)
Solicited and unsolicited injection site reaction adverse events: BCG Group - 84 days post vaccination; H4:IC31/Placebo Groups - 28 days post each vaccination
Serious adverse events, adverse events of special interest, and SUSARs: Entire study period, with a minimum of 6 months following the last dose of study vaccine</description>
        <time_frame>Study day 7 thru 6 months after last vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AERAS-404 (15 mcgH4/500 Nmol IC31)</title>
            <description>2 doses on Study Days 0 and 56
AERAS-404: The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK &amp; a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 &amp; saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.</description>
          </group>
          <group group_id="O2">
            <title>Bacillus Calmette-Guérin (BCG)</title>
            <description>1 Dose on Study Day 0
Bacillus Calmette-Guérin (BCG): BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>2 Doses on Study Days 0 and 56
Placebo: Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Profile of H4:IC31 and BCG Revaccination in HIV-uninfected, Remotely BCG Vaccinated Adolescents.</title>
          <description>Number of unsolicited and solicited adverse events recorded post vaccination.
Unsolicited adverse events: 28 days post each vaccination
Solicited adverse events: 7 days post each vaccination (with diary cards used for 7 days after each vaccination for Safety and Immunogenicity Cohort only)
Solicited and unsolicited injection site reaction adverse events: BCG Group - 84 days post vaccination; H4:IC31/Placebo Groups - 28 days post each vaccination
Serious adverse events, adverse events of special interest, and SUSARs: Entire study period, with a minimum of 6 months following the last dose of study vaccine</description>
          <units>number of AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="330"/>
                <count group_id="O3" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286"/>
                    <measurement group_id="O2" value="1257"/>
                    <measurement group_id="O3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Testing Positive for Mtb at Day 84</title>
        <description>Rates of conversion to Mtb-positive measured by QuantiFERON-TB Gold In-tube (QFT-GIT) assay. The primary evaluation of Mtb infection was QFT-GIT conversion from a negative to positive test, using the manufacturer's recommended threshold of ≥0.35 IU/mL, at any time point after Day 84 and through end of follow-up for the primary endpoint. All participants with primary QFT-GIT conversion were followed for an additional 6 months post-conversion to ascertain the sustained QFT-GIT conversion and QFT-GIT reversion endpoints. Participants with an initial QFT-GIT conversion at Month 6 or 12 were asked to return for a final QFT-GIT evaluation and assessment for TB signs and symptoms at least 24 months after their initial vaccination.
H4:IC31 compared to placebo
BCG revaccination compared to placebo</description>
        <time_frame>Study day 84 through 6 months post-conversion</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>AERAS-404 (15 mcgH4/500 Nmol IC31)</title>
            <description>2 doses on Study Days 0 and 56
AERAS-404: The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK &amp; a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 &amp; saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.</description>
          </group>
          <group group_id="O2">
            <title>Bacillus Calmette-Guérin (BCG)</title>
            <description>1 Dose on Study Day 0
Bacillus Calmette-Guérin (BCG): BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>2 Doses on Study Days 0 and 56
Placebo: Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Testing Positive for Mtb at Day 84</title>
          <description>Rates of conversion to Mtb-positive measured by QuantiFERON-TB Gold In-tube (QFT-GIT) assay. The primary evaluation of Mtb infection was QFT-GIT conversion from a negative to positive test, using the manufacturer's recommended threshold of ≥0.35 IU/mL, at any time point after Day 84 and through end of follow-up for the primary endpoint. All participants with primary QFT-GIT conversion were followed for an additional 6 months post-conversion to ascertain the sustained QFT-GIT conversion and QFT-GIT reversion endpoints. Participants with an initial QFT-GIT conversion at Month 6 or 12 were asked to return for a final QFT-GIT evaluation and assessment for TB signs and symptoms at least 24 months after their initial vaccination.
H4:IC31 compared to placebo
BCG revaccination compared to placebo</description>
          <population>Intent-to-Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Sustained Conversion to Mtb-positive</title>
        <description>Rates of sustained conversion to Mtb-positive as measured by QFT-GIT assay.
H4:IC31 compared to placebo
BCG revaccination compared to placebo</description>
        <time_frame>6 months after initial conversion</time_frame>
        <population>Modified Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>AERAS-404 (15 mcgH4/500 Nmol IC31)</title>
            <description>2 doses on Study Days 0 and 56
AERAS-404: The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK &amp; a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 &amp; saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.</description>
          </group>
          <group group_id="O2">
            <title>Bacillus Calmette-Guérin (BCG)</title>
            <description>1 Dose on Study Day 0
Bacillus Calmette-Guérin (BCG): BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>2 Doses on Study Days 0 and 56
Placebo: Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Sustained Conversion to Mtb-positive</title>
          <description>Rates of sustained conversion to Mtb-positive as measured by QFT-GIT assay.
H4:IC31 compared to placebo
BCG revaccination compared to placebo</description>
          <population>Modified Intent-to-Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Immune Response to Vaccine in HIV-uninfected, Remotely BCG-vaccinated Adolescents: o H4:IC31 o BCG Revaccination</title>
        <description>A 13 color intracellular cytokine staining assay (ICS) was performed on peripheral blood mononuclear cells (PBMC) to assess CD4+ T cells that expressed IFN-γ, TNF, IL-2, IL-17, IL-22, CD107a, and/or CD154 alone or in combination in response to stimulation with peptide pools representing the entire amino acid sequence of the TB mycobacterial antigens Ag85B and TB10.4, and BCG antigens. Responders were IFN-gamma and/or IL-2 positive.
An intracellular cytokine assay was performed on whole blood (WB) to measure the frequencies and patterns of CD4+ T cells expressing Th1 and Th17 cytokines following stimulation of whole blood with peptide pools representing the entire amino acid sequence of the TB mycobacterial antigens Ag85B and TB10.4, as well as viable BCG from the vaccine vial. Responders were IFN-gamma, IL-2, TNF, IL-17, and/or IL-22 positive.</description>
        <time_frame>Study day 70</time_frame>
        <population>Modified ITT analysis set: Safety and immunogenicity cohort</population>
        <group_list>
          <group group_id="O1">
            <title>AERAS-404 (15 mcgH4/500 Nmol IC31)</title>
            <description>2 doses on Study Days 0 and 56
AERAS-404: The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK &amp; a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 &amp; saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.</description>
          </group>
          <group group_id="O2">
            <title>Bacillus Calmette-Guérin (BCG)</title>
            <description>1 Dose on Study Day 0
Bacillus Calmette-Guérin (BCG): BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>2 Doses on Study Days 0 and 56
Placebo: Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Immune Response to Vaccine in HIV-uninfected, Remotely BCG-vaccinated Adolescents: o H4:IC31 o BCG Revaccination</title>
          <description>A 13 color intracellular cytokine staining assay (ICS) was performed on peripheral blood mononuclear cells (PBMC) to assess CD4+ T cells that expressed IFN-γ, TNF, IL-2, IL-17, IL-22, CD107a, and/or CD154 alone or in combination in response to stimulation with peptide pools representing the entire amino acid sequence of the TB mycobacterial antigens Ag85B and TB10.4, and BCG antigens. Responders were IFN-gamma and/or IL-2 positive.
An intracellular cytokine assay was performed on whole blood (WB) to measure the frequencies and patterns of CD4+ T cells expressing Th1 and Th17 cytokines following stimulation of whole blood with peptide pools representing the entire amino acid sequence of the TB mycobacterial antigens Ag85B and TB10.4, as well as viable BCG from the vaccine vial. Responders were IFN-gamma, IL-2, TNF, IL-17, and/or IL-22 positive.</description>
          <population>Modified ITT analysis set: Safety and immunogenicity cohort</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PBMC ICS: Percent of responders on day 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="16.0"/>
                    <measurement group_id="O3" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WB ICS: Percent responders on day 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited AEs: 28 days post each vaccination Solicited AEs: 7 days post each vaccination (with diary cards used for 7 days after each vaccination for Safety and Immunogenicity Cohort only) Solicited and unsolicited injection site reaction AEs: BCG Group - 84 days post vaccination; H4:IC31/Placebo Groups - 28 days post vaccination Serious adverse events, adverse events of special interest, and SUSARs: Entire study period (minimum of 6 months following last dose of study vaccine)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AERAS-404 (15 mcgH4/500 Nmol IC31)</title>
          <description>2 doses on Study Days 0 and 56
AERAS-404: The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK &amp; a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 &amp; saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.</description>
        </group>
        <group group_id="E2">
          <title>Bacillus Calmette-Guerin (BCG)</title>
          <description>1 Dose on Study Day 0
Bacillus Calmette-Guérin (BCG): BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>2 Doses on Study Days 0 and 56
Placebo: Saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="329" subjects_at_risk="330"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="330"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="330"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="330"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="330"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="330"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="330"/>
                <counts group_id="E3" events="26" subjects_affected="18" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="46" subjects_affected="34" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="27" subjects_affected="20" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="169" subjects_affected="163" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="150" subjects_affected="147" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="92" subjects_affected="90" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="171" subjects_affected="171" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="47" subjects_affected="45" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site pallor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site papule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site scab</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="147" subjects_affected="145" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site scar</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="255" subjects_affected="255" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="179" subjects_affected="172" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="104" subjects_affected="104" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Rubella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="330"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="330"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Vaccination site pustule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="330"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="330"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="330"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="330"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="330"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="330"/>
                <counts group_id="E3" events="42" subjects_affected="31" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="330"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pityriasis rosea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Hatherill</name_or_title>
      <organization>SATVI</organization>
      <phone>+27214066145</phone>
      <email>mark.hatherill@uct.ac.za</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

